Can fast-growing Eliquis overtake J&J's Xarelto? Bristol's execs think so

Eliquis, a new-age anticoagulant that once dragged well behind analysts' expectations, has seriously picked up the pace lately, rocketing to the top of Bristol-Myers Squibb's ($BMY) sales charts. And company execs don't expect it to stop there. As CEO Giovanni Caforio put it on last week's Q4 conference call, its recent performance puts the company "well on our way" to passing by a pair of hefty competitors in Johnson & Johnson ($JNJ) and Bayer's Xarelto and Boehringer Ingelheim's Pradaxa. More from FiercePharmaMarketing

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…